Important for regulators to look up from review of individual drugs or trials and ask: Are we making progress in this disease? If not, how can we change that? If so, how can we make more? This is in 2017.
Quote Tweet
This dedication toward progress in a disease rather than looking at individual drug applications requires flexibility, calculated risks, and committed people to work at FDA- Pazdur #SABCS17